Zanubrutinib (zanu) versus acalabrutinib (acala) in B-cell malignancies: an adverse event (AE)-based economic analysis
Epidemiology, Treatment Patterns, Humanistic And Economic Burden Of Biliary Tract Carcinoma: A Systematic And Targeted Literature Review
